Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Business News, In Brief

Executive Summary

Vectibix disappoints in head and neck cancer: Amgen's anti-EGFR antibody Vectibix (panitumumab) failed to meet the primary endpoint in the Phase III SPECTRUM trial in head and neck cancer, the firm announced Aug. 11, but the disappointing trial results will have little impact - as most analysts expected only modest contributions to sales of the colorectal cancer drug. Adding Vectibix to platinum-based chemotherapy in patients with recurrent and/or metastatic squamous cell head and neck cancer did not result in a statistically significant improvement in overall survival compared to chemo alone: 11.1 months versus 9.0 months. There were numeric improvements in the secondary endpoints of progression-free survival (5.8 months vs. 4.6 months) and objective response rate (36 percent vs. 25 percent), but those were not tested for statistical significance. The study enrolled 658 patients. Full data will be presented at the European Society for Medical Oncology meeting in Milan in October. In an Aug. 11 note, Lazard analyst Joel Sendak noted that Vectibix would always have challenges in taking market share in head and neck cancer from Erbitux - though the lack of effect was "somewhat surprising" given that the two agents share the same mechanism of action. Sendak sees the most opportunity for Vectibix in front-line CRC, and the most opportunity for Amgen in the pending Prolia (denosumab)

You may also be interested in...

Alzheimer's Start-Ups At A Crossroads Between Discovery And The Clinic

With big Phase III failures heating debate about the amyloid hypothesis, small biotechs must convince investors that early research is pointed in the right direction, and larger ones must design clinical trials with care

EU Approves Shire's Vpriv For Gaucher Disease, As Shortages Of Genzyme's Rival Product Ease

Shire's Vpriv gains approval in 30 European countries for Gaucher disease, but competition from rival products looks set to increase.

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts